- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07610122
Validation of the Turkish Version of the S3-NIV Questionnaire
Reliability and Validity of the Turkish Version of the Severe Respiratory Insufficiency Questionnaire for Non-Invasive Ventilation (S3-NIV)
This study aims to evaluate the psychometric properties, including reliability and validity, of the Turkish version of the Severe Respiratory Insufficiency Questionnaire for Non-Invasive Ventilation (S3-NIV). The S3-NIV is a specific tool designed to assess difficulties and compliance in patients receiving home non-invasive ventilation. A total of 120 stable patients using home NIV for at least 3 months will be enrolled across multiple centers.
Study Overview
Status
Intervention / Treatment
Detailed Description
Following the official linguistic validation process authorized by the Mapi Research Trust, this multi-center observational study will assess the psychometric validity of the Turkish S3-NIV questionnaire. Patients will complete the 11-item S3-NIV questionnaire alongside a sociodemographic and clinical data form. To evaluate test-retest reliability, a randomly selected subgroup of patients (n=40) will re-complete the questionnaire 14 to 15 days after the initial administration. Internal consistency, construct validity (via factor analysis), and criterion validity (correlations with clinical parameters such as daily NIV usage hours and blood gas values) will be analyzed.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Dilek Unsal, PT PhD(c)
- Phone Number: +90 530 4641198
- Email: fztdlkunsal@gmail.com
Study Locations
-
-
-
Istanbul, Turkey (Türkiye)
- Recruiting
- Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital
-
Contact:
- Dilek Ünsal, PT PhD(c)
- Phone Number: +905304641198
- Email: fztdlkunsal@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Adult patients with chronic respiratory failure who are followed up in the outpatient clinic and have been using a home non-invasive ventilation (NIV) device for at least 3 months.
Description
Inclusion Criteria:
- Diagnosed with chronic respiratory failure requiring home non-invasive ventilation (NIV).
- Using a home NIV device for at least 3 months.
- Being in a clinically stable phase (no exacerbation or hospitalization in the last 1 month).
- Able to understand and answer the questionnaire.
- Provided written informed consent.
Exclusion Criteria:
- Acute respiratory failure or clinical instability.
- Severe cognitive impairment or psychiatric disorders preventing reliable communication.
- Active malignancy or terminal illness with a short life expectancy.
- Refusal to provide informed consent.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Home NIV Patients
Patients with chronic respiratory failure who have been using home non-invasive ventilation (NIV) for at least 3 months and are in a clinically stable phase. |
An 11-item self-administered questionnaire designed to evaluate the difficulties and compliance of patients using home non-invasive ventilation (NIV). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Internal Consistency and Construct Validity of the Turkish S3-NIV
Time Frame: Baseline (Day 0)
|
Evaluated using Cronbach's alpha coefficient for internal consistency and Confirmatory/Exploratory Factor Analysis (CFA/EFA) to confirm the structural validity of the 11-item scale. |
Baseline (Day 0)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Test-Retest Reliability
Time Frame: 14 to 15 days after baseline
|
Evaluated using the Intraclass Correlation Coefficient (ICC) between the first and second administrations of the questionnaire in a randomly selected subgroup. |
14 to 15 days after baseline
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ipek Ozmen, Prof., Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 26/40
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
A decision on sharing individual participant data (IPD) has not yet been made. Data sharing may be considered upon reasonable request to the principal investigator after the publication of the study results.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.